CA2864008C - New compositions for treating amyotrophic lateral sclerosis - Google Patents

New compositions for treating amyotrophic lateral sclerosis Download PDF

Info

Publication number
CA2864008C
CA2864008C CA2864008A CA2864008A CA2864008C CA 2864008 C CA2864008 C CA 2864008C CA 2864008 A CA2864008 A CA 2864008A CA 2864008 A CA2864008 A CA 2864008A CA 2864008 C CA2864008 C CA 2864008C
Authority
CA
Canada
Prior art keywords
combination
baclofen
acamprosate
drug
als
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2864008A
Other languages
English (en)
French (fr)
Other versions
CA2864008A1 (en
Inventor
Daniel Cohen
Serguei Nabirochkin
Ilya Chumakov
Rodolphe HAJJ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharnext SA
Original Assignee
Pharnext SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/EP2012/053565 external-priority patent/WO2012117073A2/en
Priority claimed from PCT/EP2012/053570 external-priority patent/WO2012117076A2/en
Application filed by Pharnext SA filed Critical Pharnext SA
Priority to CA3075331A priority Critical patent/CA3075331A1/en
Publication of CA2864008A1 publication Critical patent/CA2864008A1/en
Application granted granted Critical
Publication of CA2864008C publication Critical patent/CA2864008C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA2864008A 2012-03-01 2013-02-28 New compositions for treating amyotrophic lateral sclerosis Active CA2864008C (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA3075331A CA3075331A1 (en) 2012-03-01 2013-02-28 New compositions for treating amyotrophic lateral sclerosis

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
PCT/EP2012/053565 WO2012117073A2 (en) 2011-03-01 2012-03-01 New compositions for treating neurological disorders
PCT/EP2012/053570 WO2012117076A2 (en) 2011-03-01 2012-03-01 Baclofen and acamprosate based therapy of neurogical disorders
EPPCT/EP2012/053565 2012-03-01
EPPCT/EP2012/053570 2012-03-01
PCT/EP2013/054024 WO2013127917A1 (en) 2011-03-01 2013-02-28 New compositions for treating amyotrophic lateral sclerosis

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CA3075331A Division CA3075331A1 (en) 2012-03-01 2013-02-28 New compositions for treating amyotrophic lateral sclerosis

Publications (2)

Publication Number Publication Date
CA2864008A1 CA2864008A1 (en) 2013-09-06
CA2864008C true CA2864008C (en) 2020-04-21

Family

ID=51619337

Family Applications (2)

Application Number Title Priority Date Filing Date
CA2864008A Active CA2864008C (en) 2012-03-01 2013-02-28 New compositions for treating amyotrophic lateral sclerosis
CA3075331A Abandoned CA3075331A1 (en) 2012-03-01 2013-02-28 New compositions for treating amyotrophic lateral sclerosis

Family Applications After (1)

Application Number Title Priority Date Filing Date
CA3075331A Abandoned CA3075331A1 (en) 2012-03-01 2013-02-28 New compositions for treating amyotrophic lateral sclerosis

Country Status (2)

Country Link
CA (2) CA2864008C (enExample)
IN (1) IN2014DN07989A (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12121609B2 (en) 2014-11-21 2024-10-22 Biohaven Therapeutics Ltd. Sublingual formulation of riluzole

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107735077A (zh) * 2014-11-21 2018-02-23 拜尔哈文制药股份有限公司 利鲁唑的舌下给药

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12121609B2 (en) 2014-11-21 2024-10-22 Biohaven Therapeutics Ltd. Sublingual formulation of riluzole

Also Published As

Publication number Publication date
CA2864008A1 (en) 2013-09-06
IN2014DN07989A (enExample) 2015-05-01
CA3075331A1 (en) 2013-09-06

Similar Documents

Publication Publication Date Title
DK2819664T3 (en) NEW COMPOSITIONS FOR TREATING AMYOTROPHIC LATERAL SCLEROSIS
US10682342B2 (en) Compositions for treating amyotrophic lateral sclerosis
JP6416328B2 (ja) 筋萎縮性側索硬化症の治療のための新規組成物
AU2018201436B2 (en) New therapeutic approaches for treating Parkinson's disease
US9248111B2 (en) Therapeutic approaches for treating parkinson's disease
US10010515B2 (en) Therapeutic approaches for treating Parkinson's disease
CA2864008C (en) New compositions for treating amyotrophic lateral sclerosis
EP2819664B1 (en) New compositions for treating amyotrophic lateral sclerosis
AU2018201400B2 (en) New compositions for treating amyotrophic lateral sclerosis
AU2013291970A1 (en) Baclofen and acamprosate based therapy of Macular Degeneration disorders
HK1203406B (en) New compositions for treating amyotrophic lateral sclerosis
HK1203406A1 (en) New compositions for treating amyotrophic lateral sclerosis

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20180102

H11 Ip right ceased following rejected request for revival

Free format text: ST27 STATUS EVENT CODE: T-6-6-H10-H11-H101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: TIME LIMIT FOR REVERSAL EXPIRED

Effective date: 20250828

H13 Ip right lapsed

Free format text: ST27 STATUS EVENT CODE: N-4-6-H10-H13-H100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE AND LATE FEE NOT PAID BY DEADLINE OF NOTICE

Effective date: 20251106